Aardvark Therapeutics
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic diseases and inflammation. Their lead compound, ARD-101, is an oral drug targeting bitter taste receptors to reduce hunger. This drug shows promise in treating Prader-Willi Syndrome and obesity.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $85M
Date: 09-May-2024
Investors: Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, The Prader-Willi Syndrome Association – USA, Vickers Venture Partners, Foundation for Prader-Willi Research
Markets: Biotechnology, Pharmaceuticals, Therapeutics
HQ: San Diego, California, United States
Founded:
Website: https://www.aardvarktherapeutics.com/
LinkedIn: https://www.linkedin.com/company/aardvark-therapeutics
Crunchbase: https://www.crunchbase.com/organization/aardvark-therapeutics
Leave a Comment
Comments
No comments yet.